Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation

Lynne M. Ball, Maria Ester Bernardo, Helene Roelofs, Arjan Lankester, Angela Cometa, R. Maarten Egeler, Franco Locatelli, Willem E. Fibbe

Research output: Contribution to journalArticlepeer-review

Abstract

Haploidentical hematopoietic stem-cell transplantation (HSCT) is associated with an increased risk of graft failure. Adult bone marrow-derived mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immune suppressive effects. We cotransplanted donor MSCs in 14 children undergoing transplantation of HLA-disparate CD34+ cells from a relative. While we observed a graft failure rate of 15% in 47 historic controls, all patients given MSCs showed sustained hematopoietic engraftment without any adverse reaction. In particular, children given MSCs did not experience more infections compared with controls. These data suggest that MSCs, possibly thanks to their potent immunosuppressive effect on alloreactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure in haploidentical HSC transplant recipients.

Original languageEnglish
Pages (from-to)2764-2767
Number of pages4
JournalBlood
Volume110
Issue number7
DOIs
Publication statusPublished - Oct 1 2007

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation'. Together they form a unique fingerprint.

Cite this